Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App





Coronavirus Screening Test Developed by Johns Hopkins Microbiologists

By LabMedica International staff writers
Posted on 20 Mar 2020
A team of clinical microbiologists from John Hopkins University (Baltimore, MD) have developed an in-house coronavirus screening test that could allow the health system to test about 1,000 people daily. More...
The test would help people to quickly learn if they are infected with COVID-19 and also allow doctors to test people with whom such patients have come in contact.

The test, which analyzes a nasal or oral swab, was used for the first time on March 11 by the microbiologists who performed around 85 tests during the first three days. The team expects to quickly ramp up capacity and test 180 people per day next week and 500 people in the week after that to reach 1,000 tests per day by early April. Currently, the test delivers results in about 24 hours, which the doctors hope to shorten to three hours.

“We will be able to diagnose more cases. This will allow the control of exposure,” said Heba Mostafa, M.B.B.Ch., Ph.D., assistant professor of pathology and director of the molecular virology laboratory at The Johns Hopkins Hospital.

“Testing is very important in terms of identifying cases so epidemiologists can then contact people exposed to individuals who are known to be positive and make recommendations about home isolation and further follow-up,” added Karen Carroll, M.D., professor of pathology and director of the Division of Medical Microbiology at Johns Hopkins.

Related Links:
John Hopkins University


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researchers developed a blood test that accurately distinguishes early-stage breast cancer from healthy controls and may outperform tissue biopsy in predicting recurrence risk (Image Credit: Adobe Stock)

Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk

Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.